Feature | October 31, 2013

Philips, RealView Conclude First Study to Evaluate Live 3-D Holographic Imaging in the Cath Lab

cath lab tct advanced visualization hybrid or philips realview holographic 3-D
October 31, 2013 — Philips and RealView Imaging Ltd. have completed a clinical study that demonstrated the feasibility of using an innovative live 3-D holographic visualization and interaction technology to guide minimally invasive structural heart disease procedures. In the pilot study that involved eight patients and was conducted in collaboration with the Schneider Children’s Medical Center in Petach Tikva, Israel, RealView’s visualization technology was used to display interactive, real-time 3-D holographic images acquired by Philips’ interventional X-ray and cardiac ultrasound systems.
 
In addition to viewing the patient’s heart on a 2-D screen, doctors in the interventional team were able to view detailed dynamic 3-D holographic images of the heart “floating in free space” during a minimally invasive structural heart disease procedure without using special eyewear. The doctors were also able to manipulate the projected 3-D heart structures by touching the holographic volumes in front of them. The study demonstrated the potential of the technology to enhance the context and guidance of structural heart repairs.
 
“The holographic projections enabled me to intuitively understand and interrogate the 3-D spatial anatomy of the patient’s heart, as well as to navigate and appreciate the device-tissue interaction during the procedure,” said Dr. Einat Birk, pediatric cardiologist and director, Institute of Pediatric Cardiology, Schneider Children’s Medical Center.
 
“The ability to reach into the image and apply markings on the soft tissue anatomy in the X-ray and 3-D ultrasound images would be extremely useful for guidance of these complex procedures,” said Dr. Elchanan Bruckheimer, pediatric cardiologist and director, cardiac catheterization laboratories, Schneider Children’s Medical Center.
 
Bruckheimer presented the results of the pilot study at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
“Our ultimate goal is to create the future of healthcare by delivering innovative solutions that enhance clinical capabilities and improve patient outcomes,” said Bert van Meurs, general manager, Integrated Clinical Solutions and Marketing Imaging Systems, Philips Healthcare. “By teaming up with partners that share our passion for innovation, we have been able to demonstrate the feasibility and potential value of the world’s first holographic visualization technology targeted at guiding minimally invasive cardiac procedures.”
 
“I see clear indications that 3-D medical holography will play an important role in medical imaging in the near future,” said Aviad Kaufman, CEO, RealView. “With the advancement of live 3-D imaging and increasing clinical evidence of its value for a variety of procedures, we are convinced that our holographic technology will further enhance 3-D imaging and, most importantly, improve patient care.”
 
Progress in image-guided therapies for heart diseases — from the opening of obstructed coronary arteries to catheter ablation therapy for heart arrhythmias and catheter-based structural heart repairs (for example, heart valve replacements) — have greatly increased the need for live 3-D image guidance to supplement today’s live 2-D image guidance. Live X-ray and live 3-D cardiac ultrasound imaging are typically used simultaneously to guide minimally invasive structural heart repair procedures, with the ultrasound images providing detailed insights into the heart’s soft tissue anatomy and the X-ray imaging providing visualization of catheters and heart implants.
 
The technological advancements in the acquisition of live 3-D images to guide minimally invasive procedures have also triggered the development of novel ways to visualize the data. Following the promising results produced by this pilot study, Philips and RealView Imaging will continue to explore the clinical value of combining live 3-D imaging and medical holography in interventional cardiology and other clinical areas.
 

Related Content

Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
Technavio report, renal denervation devices, 2015
News | Renal Denervation| August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
Jason Burdick, injectable hydrogels, heart failure, heart attack, American Chemical Society

Compared to other types of hydrogels being developed (left), a new hydrogel (right) can form crosslinks after injection into the heart, making the material stiffer and longer-lasting. Image courtesy of American Chemical Society.

News | Heart Failure| August 23, 2016
August 23, 2016 — During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells within
News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
DMC Heart Hospital, Detroit Medical Center, complex percutaneous intervention education course, PCI, cath lab training
News | Cath Lab| August 22, 2016
The Detroit Medical Center (DMC) Heart Hospital recently completed a Complex Percutaneous Intervention education course...
TAILOR-PCI study, antiplatelet medication, genotype, NHLBI grant
News | Antiplatelet and Anticoagulation Therapies| August 18, 2016
Researchers at the Peter Munk Cardiac Centre, Toronto, and at Mayo Clinic are leading the Tailored Antiplatelet Therapy...
Covidien, Medtronic, TurboHawk, Atherectomy system

The Medtronic TurboHawk atherectomy system. 

Feature | Atherectomy Devices| August 18, 2016 | Dave Fornell
Due to poor outcomes from percutaneous transluminal angioplasty (PTA) ballooning of vessels alone, or of stenting in
Sapien III, Sapien 3, PARTNER III, FDA approval, expanded indication, intermediate risk patients

The Sapien 3 valve has a skirt of fabric at its base that has significantly reduced issues of paravalvular leak, which was an issue with the first generation Sapien device. 

Feature | Heart Valve Technology| August 18, 2016 | Dave Fornell
August 18, 2016 — The U.S.
Corindus Corpath, Acist Medical RXi and CVi, Fairview Southdale Hospital, Minnesota, cath lab
News | Cath Lab| August 17, 2016
Corindus Vascular Robotics Inc. and Acist Medical Systems Inc. are providing Fairview Southdale Hospital, Edina, Minn...
Sponsored Content | Videos | Inventory Management| August 15, 2016
Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a chall
Overlay Init